Sylvan Group Acquires 4 Singapore Healthcare Companies for US$ 140.5 Million

Zikrul
By -
0
Sylvan Group Acquires 4 Singapore Healthcare Companies for US$ 140.5 Million


The Sylvan Group, which is also backed by members of the Hyundai and Rockefeller families, said it had bought majority stakes in four Singaporean healthcare and pharmaceutical companies for US$140.5 million.

The companies that Sylvan acquired are Juniper Biologics, which develops cancer therapy and gene therapy, and Artemis Health Ventures, a provider of orthopedic services. Radiology and imaging services companies DX Imaging and Juniper Therapeutics are two other acquisitions.

Kyungsun Chung, co-founder and managing partner of Sylvan, an impact investor, said in a statement that the investment was made from Sylvan Asia Growth Fund I, which has raised about half of its US$400 million target from investors.

"We are investing in mid-sized companies that have strong potential for social impact through their business or can be further developed by changing their value chain or have solutions to social and environmental problems," he said.

Chung added that it would raise the remaining US$200 million from its Sylvan Asia Growth Fund I target in the second half of 2023. He said the fund's focus areas would include the health, renewable energy and education sectors.

Sylvan has also received support from the likes of United Overseas Bank Singapore, Hanwha Life Insurance Korea and Kolon Industries.

"One of the reasons many family-controlled conglomerates in Asia work with us is because they also see the importance of adapting to this new changing environment, which is basically all about sustainability," added Chung.


Founded in 2019, Sylvan's strategy involves taking a majority stake in a profitable midsize company and making leveraged purchases.


Subscribe Daily Post or Follow Google News to update information quickly, Thank you..!!

Post a Comment

0Comments

Post a Comment (0)

#buttons=(Ok, Go it!) #days=(20)

Our website uses cookies to enhance your experience. Learn more
Ok, Go it!